Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹14Cr
Rev Gr TTM
Revenue Growth TTM
0.75%
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

GARWSYN
VS
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | -20.1 | -1.0 | -17.4 | -0.7 | -5.1 | -7.6 | 12.2 | -6.3 | 5.4 | -2.6 | 2.5 | -2.4 |
| 3 | 3 | 2 | 3 | 3 | 3 | 3 | 2 | 3 | 2 | 3 | 2 |
Operating Profit Operating ProfitCr |
| 2.2 | 8.3 | 3.2 | 6.6 | -5.4 | 1.5 | 2.5 | 2.4 | -3.6 | 9.6 | 10.9 | 13.7 |
Other Income Other IncomeCr | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation DepreciationCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
Growth YoY PAT Growth YoY% | 352.0 | 0.0 | | 200.0 | -77.8 | 333.3 | 115.0 | -433.3 | -92.9 | 71.4 | 300.0 | 320.0 |
| 22.9 | -1.0 | -8.1 | 1.1 | 5.4 | 2.6 | 1.1 | -3.9 | 0.4 | 4.6 | 4.2 | 8.8 |
| 0.7 | 0.1 | -0.3 | 0.1 | 0.3 | 0.1 | 0.1 | -0.2 | 0.0 | 0.2 | 0.3 | 0.4 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| 9.1 | -2.5 | 8.0 | 12.5 | 10.8 | -14.3 | -9.3 | 53.7 | -10.2 | -6.2 | 0.3 | -0.5 |
| 8 | 8 | 8 | 9 | 11 | 9 | 7 | 12 | 11 | 10 | 11 | 10 |
Operating Profit Operating ProfitCr |
| -1.4 | 1.1 | 4.9 | 5.1 | 0.3 | 3.2 | 12.8 | 7.6 | 7.5 | 3.5 | 0.5 | 7.5 |
Other Income Other IncomeCr | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Depreciation DepreciationCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 1 | 0 | -1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| 616.2 | -72.8 | 181.5 | -26.5 | -499.0 | 108.0 | 427.9 | -60.5 | 151.2 | -108.3 | 127.3 | 3,515.4 |
| 7.6 | 2.1 | 5.5 | 3.6 | -12.9 | 1.2 | 7.0 | 1.8 | 5.1 | -0.5 | 0.1 | 4.4 |
| 1.1 | 0.3 | 0.8 | 0.6 | -2.4 | 0.3 | 1.1 | 0.4 | 1.0 | -0.1 | 0.0 | 0.9 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|
Equity Capital Equity CapitalCr | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| -9 | -8 | -8 | -7 | -9 | -9 | -8 | -8 | -8 | -8 | -8 | -8 |
Current Liabilities Current LiabilitiesCr | 5 | 5 | 5 | 4 | 4 | 3 | 16 | 16 | 9 | 9 | 15 | 14 |
Non Current Liabilities Non Current LiabilitiesCr | 10 | 10 | 9 | 11 | 13 | 13 | 0 | 4 | 8 | 8 | 2 | 2 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 2 | 2 | 2 | 3 | 3 | 2 | 3 | 3 | 3 | 2 | 2 | 2 |
Non Current Assets Non Current AssetsCr | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 14 | 13 | 12 | 12 | 12 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | 0 | 0 | 0 | 0 | -2 | -1 | 0 | 1 | 1 | 0 | 0 |
Investing Cash Flow Investing Cash FlowCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 0 |
Financing Cash Flow Financing Cash FlowCr | 0 | 0 | 0 | 0 | 2 | 0 | -1 | -1 | 0 | 0 | 0 |
|
Free Cash Flow Free Cash FlowCr | 0 | 0 | 0 | 0 | -2 | -1 | 0 | 1 | 1 | 0 | 0 |
| -6.9 | 85.6 | 56.4 | 71.5 | 130.4 | -474.9 | 70.2 | 577.9 | 98.9 | -810.7 | 320.0 |
CFO To EBITDA CFO To EBITDA% | 36.5 | 157.0 | 62.9 | 50.3 | -6,107.5 | -179.6 | 38.6 | 137.6 | 67.1 | 104.6 | 77.9 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 22 | 9 | 6 | 7 | 2 | 1 | 3 | 8 | 5 | 10 | 16 |
Price To Earnings Price To Earnings | 36.7 | 54.8 | 12.2 | 20.1 | 0.0 | 5.7 | 5.3 | 36.5 | 8.3 | 0.0 | 1,395.0 |
Price To Sales Price To Sales | 2.8 | 1.2 | 0.7 | 0.7 | 0.2 | 0.1 | 0.4 | 0.7 | 0.4 | 0.9 | 1.5 |
Price To Book Price To Book | -8.3 | -3.6 | -3.1 | -4.7 | -0.8 | -0.2 | -1.4 | -3.3 | -2.5 | -4.7 | -8.2 |
| -231.8 | 151.5 | 23.9 | 34.3 | 491.0 | 45.8 | 14.6 | 21.0 | 12.4 | 40.5 | 399.4 |
Profitability Ratios Profitability Ratios |
| 39.5 | 46.7 | 49.1 | 45.9 | 43.3 | 48.5 | 54.4 | 43.5 | 42.5 | 47.1 | 43.9 |
| -1.4 | 1.1 | 4.9 | 5.1 | 0.3 | 3.2 | 12.8 | 7.6 | 7.5 | 3.5 | 0.5 |
| 7.6 | 2.1 | 5.5 | 3.6 | -12.9 | 1.2 | 7.0 | 1.8 | 5.1 | -0.5 | 0.1 |
| 34.7 | 18.3 | 26.3 | 5.4 | -12.3 | 2.6 | 10.1 | 12.2 | 17.1 | 6.8 | 5.5 |
| -22.7 | -6.6 | -25.8 | -23.4 | 48.3 | -4.0 | -27.1 | -9.0 | -29.4 | 2.3 | -0.7 |
| 4.9 | 1.3 | 3.6 | 2.5 | -10.1 | 0.8 | 4.3 | 1.4 | 3.8 | -0.3 | 0.1 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
Garware Synthetics Limited is an established Indian manufacturer specializing in high-quality synthetic materials, primarily serving the industrial brush and medical healthcare sectors. Operating under the recognized brand name **'GARFLON'**, the company has carved a niche in the production of specialized filaments and bristles, positioning itself as a key player in import substitution for critical medical components.
---
### **Core Product Portfolio & Specialized Applications**
The company operates a single primary business segment: **Nylon Bristles, Rods & Tubes**. Its manufacturing expertise lies in processing high-performance polymers into specialized forms.
* **Synthetic Bristles & Filaments:** Produced from a diverse range of materials including **Nylon 6, 66, 610, PBT (Polybutylene Terephthalate), and Polypropylene**. These are primarily supplied to the **Industrial Brush Industry**.
* **Medical Innovation (Nylon Sutures):** A significant strategic pivot for the company is the development of **Nylon Sutures**. Traditionally an imported commodity in India, Garware’s domestic production serves as a critical medical-grade alternative for healthcare providers.
* **Industrial Components:** The company also manufactures industrial **Rods & Tubes** for various engineering applications.
---
### **Manufacturing Infrastructure & Operational Capacity**
All manufacturing operations are centralized at the company’s facility in Maharashtra. While the company possesses significant installed capacity, current utilization is hampered by external and internal constraints.
| Metric | Details |
| :--- | :--- |
| **Location** | Mira Road (East), Dist. Thane - **401 104** |
| **Total Production Capacity** | **570 MT** per year |
| **Workforce** | **68 employees** (as of March 31, 2024) |
| **Brand Identity** | **'GARFLON'** |
**Energy Consumption Trends**
Energy is a primary cost driver for the company. Recent data indicates a rising cost per unit, impacting overall production overheads.
| Particulars | F.Y. 2024-2025 | F.Y. 2023-2024 | F.Y. 2022-2023 |
| :--- | :---: | :---: | :---: |
| **Electricity Consumption (Lakh KWH)** | **8.13** | **7.30** | **7.64** |
| **Total Energy Value (Rs. Lakhs)** | **89.81** | **70.80** | **65.62** |
| **Cost per Unit (Rs.)** | **27.46** | **21.95** | **19.86** |
| **Consumption per Ton of Production** | **27,461** | **21,948** | **19,858** |
---
### **Financial Performance & Capital Structure**
The company’s recent financial trajectory shows a strategic shift toward profitability over aggressive revenue growth. In **FY 2022-23**, the company achieved a significant **151% increase in Net Profit** despite a contraction in top-line revenue.
**Key Financial Metrics**
| Metric | FY 2022-23 (INR) | FY 2021-22 (INR) | Growth/Change |
| :--- | :--- | :--- | :--- |
| **Revenue from Operations** | **11,40,05,668** | **12,70,12,821** | **-10.24%** |
| **Net Profit** | **57,82,273** | **23,02,463** | **+151.13%** |
| **Basic/Diluted EPS** | **1.00** | **0.40** | **+150.00%** |
| **Paid-up Capital** | **5,80,89,000** | **5,80,89,000** | **0%** |
**Capital Details:**
* **Authorized Share Capital:** **Rs. 10,00,00,000** (99.5 Lakh Equity Shares and 5,000 Preference Shares).
* **Paid-up Equity Capital:** **Rs. 5,80,89,000** (58,08,900 Equity Shares at **Rs. 10** each).
* **Dividend Policy:** The Board did **not recommend a dividend** for the recent fiscal years, opting to retain earnings to bolster financial stability and fund future expansion.
---
### **Strategic Leadership & Governance**
The company has recently stabilized its leadership team with long-term appointments to oversee its next phase of growth.
* **Executive Leadership:**
* **Ms. Ujwala Somnath Tate (CEO):** Appointed for a **5-year term** ending **December 2029**.
* **Mr. Sunder Moolya (Whole-time Director):** Re-appointed for a **5-year term** ending **May 2029**.
* **Mrs. Shilpa Parab (Independent Director):** Re-appointed for a second **5-year term** ending **September 2029**.
* **Operational Support:** Following an NCLT-approved merger, the company transitioned its Registrar and Share Transfer Agent (RTA) to **Link Intime India Private Limited** in **April 2024**.
* **Compliance Framework:** The company adheres to **Ind AS** and maintains an **Audit Committee** to oversee internal controls, though it currently lacks a formal **Internal Auditor** as per **Section 138 of the Companies Act**.
---
### **Growth Strategy & Market Outlook**
Management is positioning the company to capitalize on the projected **7.5% growth** in the Indian industrial and services sectors.
* **Import Substitution:** By focusing on high-quality standards, the company aims to replace expensive imported synthetic materials, particularly in the medical sector.
* **Technology Adaptation:** While there are no active formal R&D projects, the company focuses on **Technology Adaptation and Innovation** to refine the **Garflon** product line.
* **Market Expansion:** The Board is actively exploring new business avenues within the **Garflon** field to diversify revenue streams.
---
### **Risk Factors & Operational Constraints**
Investors should note several headwinds that impact the company’s ability to scale:
* **Financial Constraints:** A persistent **scarcity of Working Capital** is the primary factor preventing the company from reaching its full **570 MT** production capacity.
* **Input Cost Volatility:** As a manufacturer of petro-based products, the company is highly sensitive to **oil price fluctuations**. High raw material costs have historically pressured profit margins.
* **Infrastructure Issues:** The Thane facility faces significant **power shortages** and frequent power-cutting, leading to production losses.
* **Regulatory & Listing Risks:**
* The **Calcutta Stock Exchange** has previously flagged non-compliance with **Minimum Public Shareholding** requirements, leading to the freezing of certain promoter demat accounts.
* **Contingent Liabilities:** The company faces **Rs. 110.11 Lakhs** in Provident Fund-related claims and **Rs. 0.15 Lakhs** in Income Tax disputes as of **FY 2024-25**.
* **Property Disputes:** Title deeds for certain immovable properties are not currently held in the company’s name and are subject to legal dispute.
* **Competitive Landscape:** The company faces intense pressure from the **unorganized sector**, which often competes on price rather than the high-quality standards maintained by Garware.